Caesars Entertainment misses Q2 earnings expectations, shares edge lower
Vaxcyte, Inc. (NASDAQ:PCVX), a $4.62 billion market cap biotechnology company specializing in biological products, announced the appointment of Dr. Olivier Brandicourt to its Board of Directors as a Class III director, effective immediately. According to InvestingPro data, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 12.75. Dr. Brandicourt’s term is set to expire at the company’s annual meeting of stockholders in 2026.
Dr. Brandicourt was appointed following the recommendation of the Nominating and Corporate Governance Committee and has been deemed an independent director under Nasdaq’s listing standards. His selection comes at a challenging time for the company, with InvestingPro data showing the stock has declined 66.6% over the past six months. His selection was not influenced by any prior arrangements or understandings with other parties, and no reportable transactions exist between him and Vaxcyte.
In line with Vaxcyte’s non-employee director compensation program, Dr. Brandicourt will receive an initial equity award worth $800,000, which will vest over a period of 36 months. Additionally, he is eligible for an annual equity award valued at $450,000, comprising both stock options and restricted stock units, vesting over a year or until the next annual stockholders’ meeting, whichever comes first. These grants are subject to continuous service and the terms of the company’s 2020 Equity Incentive Plan.
Furthermore, Dr. Brandicourt will receive a cash retainer of $50,000 annually for his service on the Board, prorated for partial years of service. Vaxcyte has also entered into a standard indemnification agreement with Dr. Brandicourt.
The information in this article is based on a press release statement filed with the Securities and Exchange Commission. Investors should note that Vaxcyte is scheduled to report its next earnings on May 12, 2025. For comprehensive analysis and additional insights, access the detailed Pro Research Report available on InvestingPro, which covers what really matters about this and 1,400+ other top stocks.
In other recent news, Vaxcyte has made several significant announcements that have captured the attention of investors. The company appointed Dr. Olivier Brandicourt, former CEO of Sanofi (NASDAQ:SNY), to its Board of Directors, bringing his extensive experience in the biopharmaceutical industry to Vaxcyte’s ongoing efforts in vaccine innovation. Vaxcyte is advancing its pneumococcal conjugate vaccine candidates, VAX-31 and VAX-24, through clinical development, with VAX-31 moving into a Phase 3 adult clinical program. Additionally, Cantor Fitzgerald initiated coverage of Vaxcyte with an Overweight rating, expressing optimism about the company’s long-term prospects despite some challenges with mixed VAX-24 pediatric data. Meanwhile, Goldman Sachs adjusted its price target for Vaxcyte, reducing it to $100 from $138, while maintaining a Buy rating after VAX-24’s Phase 2 results in infants did not meet certain criteria. Jefferies also reiterated its Buy rating, maintaining a price target of $146, citing positive infant study results for VAX-31 as a significant factor. These developments underscore Vaxcyte’s ongoing commitment to enhancing its vaccine portfolio and navigating the complex regulatory landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.